drugset

Drugs / C1-INH

Follow last change Sep 2022 re-read 3 minutes ago

C1-INH

also known as Berinert

Developed for: transplant rejection
Investigated by: CSL Behring · NYU Langone Health

Trials 1

today NCT02936479 · Ph 2

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT02936479	Oct 2016 → Oct 2018	transplant rejection	NYU Langone Health	Completed	No outcome recorded

Press releases naming this drug 14 releases

Date	Issuer	Release
2022-09-26	CSL Behring	CSL Receives Manufacturing and Marketing Authorization in Japan for “Berinert® S.C. Injection 2000,” as a Medicine for prevention of Acute Hereditary Angioedema (HAE) attacks csl.com ↗
2021-08-03	CSL Behring	FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience csl.com ↗
2016-07-18	CSL Behring	U.S. FDA Approves CSL Behring’s Berinert® as the First and Only Pediatric Treatment for Hereditary Angioedema (HAE) csl.com ↗
2014-07-30	CSL Behring	Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant csl.com ↗
2014-07-03	CSL Behring	Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant csl.com ↗
2014-02-20	CSL Behring	First patient enrolled in phase III of COMPACT, a study of volume-reduced subcutaneous C1-INH for prevention of Hereditary Angioedema (HAE) attacks csl.com ↗
2013-04-16	CSL Behring	CSL Behring Receives European Health Authorities’ Approval of Berinert® for Short-Term Prophylaxis in Adults and Children csl.com ↗
2013-02-23	CSL Behring	CSL Behring Analysis Shows Berinert® Provides Significant Relief from Cutaneous Attacks of Hereditary Angioedema csl.com ↗
2012-03-06	CSL Behring	CSL Behring Study Confirms Early Treatment with Berinert Provides Faster Resolution of Acute Hereditary Angioedema Symptoms csl.com ↗
2012-01-03	CSL Behring	CSL Behring Receives FDA Approval of Expanded Label on Berinert®; for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema csl.com ↗
2011-08-25	CSL Behring	CSL Behring Receives European Health Authorities’ Approval for Self-Administration of Berinert csl.com ↗
2010-06-02	CSL Behring	CSL Behring Receives Canadian Notice of Compliance for Berinert® csl.com ↗
2010-01-27	CSL Behring	CSL Behring Launches Berinert® Expert Network (B.E.N.™), Support System for Hereditary Angioedema Healthcare Providers, Patients and Caregivers csl.com ↗
2009-10-12	CSL Behring	CSL Behring Announces FDA Approval of Berinert®, First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S. csl.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	C1-INH	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02936479 ↗
Known as	Berinert	“are given the complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing antibody mediated injury.” NCT02936479 ↗
Action	Inhibit	“the complement inhibitor C1-INH” NCT02936479 ↗